Document Detail


Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.
MedLine Citation:
PMID:  12457271     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Although smoked marijuana contains at least 60 cannabinoids, delta(9)-tetrahydrocannabinol (delta(9)-THC) is presumed to be the cannabinoid primarily responsible for many marijuana-related effects, including increased food intake and subjective effects. Yet, there has been no systematic comparison of repeated doses of oral delta(9)-THC with repeated doses of smoked marijuana in the same individuals. OBJECTIVE: To compare the effects of oral delta(9)-THC and smoked marijuana in humans under controlled laboratory conditions. METHODS: Eleven healthy research volunteers, who reported smoking an average of six marijuana cigarettes per day, completed an 18-day residential study. Marijuana cigarettes (3.1% delta(9)-THC, q.i.d.) were smoked or delta(9)-THC (20 mg, q.i.d.) was taken orally using a staggered, double-blind, double-dummy procedure for three consecutive days. Four days of placebo administration separated each active drug condition. Psychomotor task performance, subjective effects, and food intake were measured throughout the day. RESULTS: Relative to placebo baseline, oral delta(9)-THC and smoked marijuana produced similar subjective-effect ratings (e.g., "high" and "mellow"), although some effects of smoked marijuana were more pronounced and less prone to the development of tolerance. Additionally, participants reported "negative" subjective effects (e.g., "irritable" and "miserable") during the days after smoking marijuana but not after oral delta(9)-THC. Both drugs increased food intake for 3 days of drug administration, but had little effect on psychomotor performance. CONCLUSION: These results indicate that the behavioral profile of effects of smoked marijuana (3.1% delta(9)-THC) is similar to the effects of oral delta(9)-THC (20 mg), with some subtle differences.
Authors:
Carl L Hart; Amie S Ward; Margaret Haney; Sandra D Comer; Richard W Foltin; Marian W Fischman
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2002-09-14
Journal Detail:
Title:  Psychopharmacology     Volume:  164     ISSN:  0033-3158     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-11-28     Completed Date:  2003-04-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  407-15     Citation Subset:  IM    
Affiliation:
Division on Substance Abuse, New York State Psychiatric Institute, New York, NY 10032, USA. clh42@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Attention / drug effects*
Double-Blind Method
Drug Tolerance
Eating / drug effects*
Euphoria / drug effects*
Female
Humans
Irritable Mood / drug effects
Male
Marijuana Smoking / psychology*
Psychomotor Performance / drug effects*
Tetrahydrocannabinol / administration & dosage*
Grant Support
ID/Acronym/Agency:
DA-03746/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
1972-08-3/Tetrahydrocannabinol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ketamine does not decrease striatal dopamine D2 receptor binding in man.
Next Document:  Heroin-associated environmental stimuli modulate the expression of inducible nitric oxide synthase i...